MODERN LOOK AT THE TREATMENT OF ONYCHOMYCOSIS


Cite item

Full Text

Abstract

The article presents current data for the etiology and prevalence of onychomycosis in the world, some features of the pathogenesis, clinical manifestations, triggering factors for these diseases, as well as the approaches to the treatment of mycotic infections. The effectiveness of systemic therapy, as well as the possibility of using the drug in the form of nail lacquer for monotherapy (eg, Batrafen nail lacquer containing cyclopirox) and combination therapy, as well as for the prevention of onychomycosis, is presented.

References

  1. Кожные болезни и инфекции, передающиеся половым путем / Под редакцией Ю.С. Бутова. М., 2002. C. 400.
  2. Скрипкин Ю.К., Бутов Ю.С. Клиниченская дерматовенеролдогия. М., 2009.
  3. Сергеев А.Ю. Грибковые заболевания ногтей. М., 2001. С. 155.
  4. Сергеев А.Ю. Подход к клинической оценке онихомикоза и определению схемы противогрибковой терапии на основании КИОТОС // Российский журнал кожных и венерических болезней. 2001. № 3. С. 33-37.
  5. Baran R, Hay RJ, Garduno JI. Review of antifungal therapy and the severity index for assessing onychomycosis: part I. J Dermatolog Treat 2008;19(2):72-81.
  6. Bassiri-Jahromi S, Khaksari AA. Epidemiological survey of dermatophytosis in Tehran, Iran, from 2000 to 2005. J Dermatol Venereol Leprol 2009;75(2):142-7.
  7. Baylancicek S, Serin GM, Ciprut A, et al. Ototoxic effect of topical ciclopirox as an antimycotic preparation. Otol Neurotol. 2008;29(7):910-3
  8. Bohn Manfred, Kraemer Karl Th. «Dermatopharmacology of ciclopirox nail lacqer topical solution 8 % in the treatment of onychomycosis», supplement to journal of the American Academy of dermatology "Ciclopyrox Nail Lacquer: The first prescription topical therapy for onychomycosis". 2000;43(4):57-69.
  9. Dicle O, Parmaksizoglu B, Gurkan A, et al. Skin infections in 401 renal transplant recipients in southern Turkey. Exp Clin Transplant 2009;7(2):133-6.
  10. Flores JM, Castillo VB, Franco FC, et al. Superficial fungal infections: clinical and epidemiological study in adolescents from marginal districts of Lima and Callao, Peru. J Infect Dev Ctries 2009;3(4):313-7.
  11. Malay DS, Yi S, Borowsky P, et al. Efficacy of debridement alone versus debridement combined with topical antifungal nail lacquer for the treatment of pedal onychomycosis: a randomized, controlled trial. J Foot Ankle Surg 2009;48(3):294-308.
  12. Monti D, Saccomani L, Chetoni P, et al. Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity. Br J Dermatol 2010;162(2):311-7
  13. Pelegrini A, Takahashi JP, Pereira Cde Q, et al. Incidence of dermatophytosis in a public hospital of São Bernardo do Campo, São Paulo State, Brazil. Rev Iberoam Micol 2009;26(2):118-20.
  14. Romero-Cerecero O, Zamilpa A, Jimenez-Ferrer JE, et al. Double-blind clinical trial for evaluating the effectiveness and tolerability of Ageratina pichinchensis extract on patients with mild to moderate onychomycosis. A comparative study with ciclopirox. Planta Med 2008;74(12):1430-5.
  15. S. Nolting, H.Ulbricht, K.Worz. Jatros Dermatologie - Haut- und Geschlechtskrankheiten 1997;11(12):20-26.
  16. Schaller M, Borelli C, Berger U, et al. Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection. Med Mycol 2009;47(7):753-8.
  17. Shemer A, Nathansohn N, Trau H, et al. Ciclopirox nail lacquer for the treatment of onychomycosis: an open non-comparative study. J Dermatol 2010;37(2):137-9.
  18. Welsh O, Vera-Cabrera L, Welsh E. Onychomycosis. Clin Dermatol 20104;28(2):151-9.
  19. Yenişehirli G, Bulut Y, Sezer E, et al. Onychomycosis infections in the Middle Black Sea Region, Turkey. Int J Dermatol 2009;48(9):956-9.
  20. Zhou H, Shen T, Luo Y, et al. The antitumor activity of the fungicide ciclopirox. Int J Cancer 2010:11.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies